Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02651727 · ClinicalTrials.gov registry record · Phase 1
Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects
A Phase 1 study, sponsored by Verastem.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT02651727: Clinical Trial Phase 1 study, sponsored by Verastem.
NCT02651727 is a Phase 1 study that was terminated before completion, run by Verastem. The registered enrollment target is 13 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02651727, a Phase 1 study, was terminated before completion, sponsored by Verastem.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate increasing dose levels of VS-4718 administered in combination with gemcitabine and nab-paclitaxel in subjects with advanced cancer and to determine a recommended Phase 2 dose (RP2D) for further development of this combination in subjects with untreated advanced pancreatic cancer.
Primary Outcome
Dose Escalation Phase: Frequency of DLTs at each dose level associated with administration of VS-4718 in combination with gemcitabine and nab-paclitaxel
Interventions
- DRUG Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine
- DRUG Part B, Cohort 2- VS4718, nab-paclitaxel, gemcitabine
- DRUG Part A- VS-4718, nab-paclitaxel, gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2015-09 |
| Est. Completion | 2017-01 |
| Phase | Phase 1 |
Why NCT02651727 stopped before completion
NCT02651727 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 3 interventions - of which Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine is the first listed.
NCT02651727 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02651727 about?
NCT02651727 is a clinical study titled "Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects". The purpose of this study is to evaluate increasing dose levels of VS-4718 administered in combination with gemcitabine and nab-paclitaxel in subjects with advanced cancer and to determine a recommended Phase 2 dose (RP2D) for further development of this combination in subjects with untreated advanc...
What is the current status of trial NCT02651727?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2015-09. Estimated completion is 2017-01.
What interventions are being tested in trial NCT02651727?
The interventions under investigation include: Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine (DRUG), Part B, Cohort 2- VS4718, nab-paclitaxel, gemcitabine (DRUG), Part A- VS-4718, nab-paclitaxel, gemcitabine (DRUG).
Who is sponsoring clinical trial NCT02651727?
This trial is sponsored by Verastem, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02651727's enrollment target sits among peer trials
13 1847th of 2000 higher than 149 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia